Importantly, 8/11 (73%) CBL variants were in cases classified as myeloproliferative-CMML (MP-CMML) based on WCC (Fig 1G), and 9/11 (82%) classified as CMML-1 or -2 based on BM blast percentage (Fig 1H) according to the 2016 WHO classification, linking CBL mutations not just to a proliferative phenotype but to more advanced stages of the disease, and therefore, to increased risk of progression to AML [50]. Here, CBL is linked to chronic myelomonocytic leukemia.